Diagnostic performance of magnetic resonance imaging-based radiomics for detecting prostate cancer: A systematic review and meta-analysis

Table 2 Results of the subgroup analysis, 95% confidence intervals

	Number of studies	Sensitivity			P value	Specificity			P value	AUC
		Sensitivity	P value	I2		Specificity	P value	I2
Overall	49	0.84 (0.81-0.87)	< 0.01	93.08 (91.76-94.40)		0.78 (0.70-0.84)	< 0.01	94.68 (93.75-95.62)		0.88 (0.85-0.91)
Sequences					< 0.01				< 0.01
mpMRI with DCE	20	0.88 (0.84-0.91)	< 0.01	72.75 (60.62-84.87)		0.83 (0.76-0.88)	< 0.01	84.66 (78.82-90.50)		0.82 (0.81-0.97)
mpMRI without DCE	29	0.82 (0.77-0.87)	< 0.01	94.41 (93.11-95.71)		0.73 (0.67-0.83)	< 0.01	95.90 (95.03-96.77)		0.87 (0.81-0.94)
Lesion segmentation					< 0.01				< 0.01
2D	7	0.79 (0.71-0.83)	< 0.01	92.54 (88.50-96.59)		0.76 (0.73-0.83)	< 0.01	93.33 (89.82-96.84)		0.78 (0.73-0.81)
3D	42	0.85 (0.82-0.88)	< 0.01	92.21 (91.43-94.38)		0.86 (0.77-0.89)	< 0.01	94.56 (93.52-95.60)		0.86 (0.82-0.95)
Tumor aggressiveness					< 0.01				< 0.01
csPCa	30	0.85 (0.82-0.88)	< 0.01	95.02 (93.92-96.12)		0.87 (0.84-0.92)	< 0.01	96.21 (95.44-96.96)		0.93 (0.81-0.95)
Non-csPCa	19	0.71 (0.63-0.77)	< 0.01	69.89 (55.77-84.00)		0.78 (0.73-0.82)	< 0.01	83.84 (77.44-90.25)		0.76 (0.72-0.83)

AUC: Area under the curve; mpMRI: Multiparametric magnetic resonance imaging; DCE: Dynamic contrast enhancement; csPCa: Clinically significant prostate cancer; Non-csPCa: Nonclinically significant prostate cancer.